Alnylam says heart disease drug meets goal in late-stage trial
![Photo: Martin Havtorn Petersen/MedWatch](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11070373.ece/ALTERNATES/schema-16_9/IMG_20180412_151023.jpg)
Alnylam Pharmaceuticals Inc.’s Onpattro met the main goal of a late-stage trial in patients with a form of heart disease, paving the way for the company to seek wider approval from US regulators.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Former Alnylam CEO appointed new chair of Hemab
For subscribers
CHMP approves 11 drugs at July meeting
For subscribers